Antisense drug discovery and development.

Numerous chemically modified oligonucleotides have been developed so far and show their own unique chemical properties and pharmacodynamic/pharmacokinetic characteristics. Among all non-natural nucleotides, to the best of our knowledge, only five chemistries are currently being tested in clinical trials: phosphorothioate, 2´-O-methyl RNA, 2´-O-methoxyethyl RNA, 2´,4´-bridged nucleic acid/locked nucleic acid and the phosphorodiamidate morpholino oligomer. Since phosphorothioate modification can improve the pharmacokinetics of oligonucleotides, this modification is currently used in combination with all other modifications except phosphorodiamidate morpholino oligomer. For the treatment of metabolic, cardiovascular, cancer and other systemic diseases, the phosphorothioate class of drugs is obviously helpful, while superior efficacies can be observed in phosphorodiamidate morpholino oligomer compared to other classes of oligonucleotides for the treatment of Duchenne muscular dystrophy. Which properties of antisense molecules are actually essential for clinical applications? In this article, we provide an overview of the medicinal chemistry of existing non-natural antisense molecules, as well as their clinical applications, to discuss which properties of antisense oligonuculeotides affect therapeutic potency.

[1]  BRIDGED NUCLEIC ACIDS: DEVELOPMENT, SYNTHESIS AND PROPERTIES , 2010 .

[2]  D. Tribble,et al.  Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. , 2009, Biochemical pharmacology.

[3]  M. Colvin,et al.  Structural Studies of a Borane-Modified Phosphate Diester Linkage: Ab Initio Calculations on the Dimethylboranophosphate Anion and the Single-Crystal X-ray Structure of Its Diisopropylammonium Salt. , 1998, Inorganic chemistry.

[4]  R. T. Walker,et al.  The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues. , 1991, Journal of medicinal chemistry.

[5]  V. Erdmann,et al.  Design of antisense oligonucleotides stabilized by locked nucleic acids. , 2002, Nucleic acids research.

[6]  M. Caruthers,et al.  Synthesis of deoxydinucleoside phosphorodithioates , 1991 .

[7]  B. Potter,et al.  Synthesis and configurational analysis of a dinucleoside phosphate isotopically chiral at phosphorus. Stereochemical course of Penicillium citrum nuclease P1 reaction. , 1983, Biochemistry.

[8]  P. Iversen,et al.  Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. , 2005, Current opinion in pharmacology.

[9]  M. Gordon.  Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia , 2008 .

[10]  T. P. Prakash,et al.  2'-Modified oligonucleotides for antisense therapeutics. , 2007, Current topics in medicinal chemistry.

[11]  Daniele Canzio,et al.  Incorporation of positively charged ribonucleic guanidine linkages into oligodeoxyribonucleotides: Development of potent antisense agents. , 2008, Bioorganic & medicinal chemistry letters.

[12]  E. Lesnik,et al.  2'-O-[2-[N,N-(dialkyl)aminooxy]ethyl]-modified antisense oligonucleotides. , 2000, Organic letters.

[13]  S. Kauppinen,et al.  Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.

[14]  M. Manoharan,et al.  Structural rationalization of a large difference in RNA affinity despite a small difference in chemistry between two 2'-O-modified nucleic acid analogues. , 2004, Journal of the American Chemical Society.

[15]  S. Kauppinen,et al.  LNA-mediated microRNA silencing in non-human primates , 2008, Nature.

[16]  A. Murakami,et al.  Hybridization arrest of globin synthesis in rabbit reticulocyte lysates and cells by oligodeoxyribonucleoside methylphosphonates. , 1985, Biochemistry.

[17]  J. Cohen,et al.  Evaluation of some properties of a phosphorodithioate oligodeoxyribonucleotide for antisense application. , 1993, Nucleic acids research.

[18]  K. Jayaraman,et al.  Biochemical and biological effects of nonionic nucleic acid methylphosphonates. , 1981, Biochemistry.

[19]  Akinori Nakamura,et al.  Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogs , 2009, Annals of neurology.

[20]  W. Pathmasiri,et al.  Five- and six-membered conformationally locked 2',4'-carbocyclic ribo-thymidines: synthesis, structure, and biochemical studies. , 2007, Journal of the American Chemical Society.

[21]  K. Ganesh,et al.  Conformationally constrained PNA analogues: structural evolution toward DNA/RNA binding selectivity. , 2005, Accounts of chemical research.

[22]  Peter E. Nielsen,et al.  LNA (Locked Nucleic Acids): Synthesis and High-Affinity Nucleic Acid Recognition. , 1998 .

[23]  M. Egli,et al.  Consequences of Replacing the DNA 3‘-Oxygen by an Amino Group: High-Resolution Crystal Structure of a Fully Modified N3‘ → P5‘ Phosphoramidate DNA Dodecamer Duplex† , 1998 .

[24]  P. Nielsen,et al.  Synthesis of functionalized carbocyclic locked nucleic acid analogues by ring-closing diene and enyne metathesis and their influence on nucleic acid stability and structure. , 2009, The Journal of organic chemistry.

[25]  M. Caruthers,et al.  Biochemical and physicochemical properties of phosphorodithioate DNA. , 1996, Biochemistry.

[26]  W. Stec,et al.  Diastereomers of Nucleoside 3'-O-(2-Thio-1,3,2-oxathia(selena)phospholanes): Building Blocks for Stereocontrolled Synthesis of Oligo(nucleoside phosphorothioate)s , 1995 .

[27]  Bernard Bendriem,et al.  In vivo imaging of oligonucleotides with positron emission tomography , 1998, Nature Medicine.

[28]  Stephen J. Morris,et al.  Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Peter E. Nielsen,et al.  PNA technology , 2004, Molecular biotechnology.

[30]  B. Shaw,et al.  Boron-containing oligodeoxyribonucleotide 14mer duplexes: enzymatic synthesis and melting studies. , 1995, Nucleic acids research.

[31]  Y. Hari,et al.  Selective recognition of CG interruption by 2′,4′-BNA having 1-isoquinolone as a nucleobase in a pyrimidine motif triplex formation ☆ , 2003 .

[32]  Y. Hari,et al.  Synthesis and properties of 2'-O,4'-C-methyleneoxymethylene bridged nucleic acid. , 2006, Bioorganic & medicinal chemistry.

[33]  B. Froehler,et al.  Oligodeoxynucleotides containing 5-(1-propynyl)-2′-deoxyuridine formacetal and thioformacetal dimer synthons , 1994 .

[34]  P. Herdewijn.  Nucleic Acids with a Six‐Membered ‘Carbohydrate’ Mimic in the Backbone , 2010, Chemistry & biodiversity.

[35]  S. Mccurdy,et al.  N3'-->P5' Oligodeoxyribonucleotide Phosphoramidates: A New Method of Synthesis Based on a Phosphoramidite Amine-Exchange Reaction. , 1997, The Journal of organic chemistry.

[36]  R. T. Walker,et al.  Investigation of some properties of oligodeoxynucleotides containing 4'-thio-2'-deoxynucleotides: duplex hybridization and nuclease sensitivity. , 1996, Nucleic acids research.

[37]  P. D. Cook,et al.  Oligodeoxynucleotides containing 2'-O-modified adenosine: synthesis and effects on stability of DNA:RNA duplexes. , 1993, Biochemistry.

[38]  E. Lesnik,et al.  2′‐O‐{2‐[N,N‐(Dialkyl)aminooxy]ethyl}‐Modified Antisense Oligonucleotides. , 2001 .

[39]  Sergei M Gryaznov,et al.  Oligonucleotide N3′→P5′ Phosphoramidates and Thio‐Phoshoramidates as Potential Therapeutic Agents , 2010, Chemistry & biodiversity.

[40]  R. Strömberg,et al.  Hydrolytic Reactions of the Diastereomeric Phosphoromonothioate Analogs of Uridylyl(3',5')uridine: Kinetics and Mechanisms for Desulfurization, Phosphoester Hydrolysis, and Transesterification to the 2',5'-Isomers , 1995 .

[41]  N. Minakawa,et al.  Practical synthesis of 2'-deoxy-4'-thioribonucleosides: substrates for the synthesis of 4'-thioDNA. , 2005, The Journal of organic chemistry.

[42]  E. Lesnik,et al.  Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. , 2001, The Journal of pharmacology and experimental therapeutics.

[43]  Stanley T. Crooke,et al.  Antisense Research and Applications , 1993 .

[44]  G. V. Ommen,et al.  Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells , 2004, Gene Therapy.

[45]  J. Summerton,et al.  Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. , 1989, Nucleic acids research.

[46]  W. Stec,et al.  Stereodifferentiation--the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H. , 1995, Nucleic acids research.

[47]  Deepak Bhatnagar,et al.  Promising nucleic acid analogs and mimics: characteristic features and applications of PNA, LNA, and morpholino , 2006, Applied Microbiology and Biotechnology.

[48]  S. Obika,et al.  3'-amino-2',4'-BNA: novel bridged nucleic acids having an N3'-->P5' phosphoramidate linkage. , 2001, Chemical communications.

[49]  M. Egli,et al.  Crystal structures of B-DNA with incorporated 2'-deoxy-2'-fluoro-arabino-furanosyl thymines: implications of conformational preorganization for duplex stability. , 1998, Nucleic acids research.

[50]  B. Calabretta,et al.  Antileukemia effect of c-myc N3'-->P5' phosphoramidate antisense oligonucleotides in vivo. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[51]  M. Teplova,et al.  X-ray crystal structure of a locked nucleic acid (LNA) duplex composed of a palindromic 10-mer DNA strand containing one LNA thymine monomer , 2001 .

[52]  B. Shaw,et al.  Boranophosphates as mimics of natural phosphodiesters in DNA. , 2001, Current medicinal chemistry.

[53]  S. Crooke.  Antisense Drug Technology : Principles, Strategies, and Applications, Second Edition , 2007 .

[54]  R. T. Walker,et al.  Synthesis and properties of oligodeoxynucleotides containing the analogue 2'-deoxy-4'-thiothymidine. , 1993, Nucleic acids research.

[55]  M. Stephenson,et al.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Westergaard,et al.  Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. , 2003, Nucleic acids research.

[57]  S. Crooke.  Progress in antisense technology. , 2004, Annual review of medicine.

[58]  M. Bergström,et al.  Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[59]  S. Wilton,et al.  Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide , 2006, The journal of gene medicine.

[60]  Jon D Moulton,et al.  Gene Knockdowns in Adult Animals: PPMOs and Vivo-Morpholinos , 2009, Molecules.

[61]  T. C. Bruice,et al.  Ribonucleic guanidine demonstrates an unexpected marked preference for complementary DNA rather than RNA. , 2006, Bioorganic & medicinal chemistry.

[62]  N. Minakawa,et al.  Unexpected A-form formation of 4′-thioDNA in solution, revealed by NMR, and the implications as to the mechanism of nuclease resistance , 2008, Nucleic acids research.

[63]  T. C. Bruice,et al.  Complexation of single strand telomere and telomerase RNA template polyanions by deoxyribonucleic guanidine (DNG) polycations: plausible anticancer agents. , 2008, Bioorganic & medicinal chemistry letters.

[64]  N. Minakawa,et al.  Synthesis and characterization of 2′-modified-4′-thioRNA: a comprehensive comparison of nuclease stability , 2009, Nucleic acids research.

[65]  K. Miyashita,et al.  Highly stable pyrimidine-motif triplex formation at physiological pH values by a bridged nucleic acid analogue. , 2007, Angewandte Chemie.

[66]  V V Demidov,et al.  Stability of peptide nucleic acids in human serum and cellular extracts. , 1994, Biochemical pharmacology.

[67]  R. Yu,et al.  Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100 , 2007, Drug Metabolism and Disposition.

[68]  A. Noronha,et al.  Synthesis and biophysical properties of arabinonucleic acids (ANA): circular dichroic spectra, melting temperatures, and ribonuclease H susceptibility of ANA.RNA hybrid duplexes. , 2000, Biochemistry.

[69]  Sanjay Goel,et al.  A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers , 2005, Investigational New Drugs.

[70]  M. Caruthers,et al.  Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytidine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[71]  S. Crooke,et al.  Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. , 1997, Biochemistry.

[72]  B. Laster,et al.  Boron Containing Nucleic Acids , 1992 .

[73]  E. Uhlmann,et al.  Antisense oligonucleotides: a new therapeutic principle , 1990 .

[74]  A. Levin,et al.  Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. , 2001, The Journal of pharmacology and experimental therapeutics.

[75]  D. Lloyd,et al.  Oligonucleotide N3'-->P5' phosphoramidates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[76]  C. Wilds,et al.  2'-Deoxy-2'-fluoro-beta-D-arabinonucleosides and oligonucleotides (2'F-ANA): synthesis and physicochemical studies. , 2000, Nucleic acids research.

[77]  P. D. Cook,et al.  Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. , 1993, Journal of medicinal chemistry.

[78]  G. van Ommen,et al.  In vivo comparison of 2′‐O‐methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping , 2009, The journal of gene medicine.

[79]  J. Wengel,et al.  Functionalized LNA (locked nucleic acid): high-affinity hybridization of oligonucleotides containing N-acylated and N-alkylated 2'-amino-LNA monomers. , 2003, Chemical communications.

[80]  P. D. Cook,et al.  Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA , 1999, Nature Structural Biology.

[81]  K. Davies,et al.  Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[82]  E. Kawashima,et al.  Synthesis of oligonucleoside phosphorodithioates on a solid support by the H-phosphonothioate method , 2006 .

[83]  K. Miyashita,et al.  Design, synthesis, and properties of 2',4'-BNA(NC): a bridged nucleic acid analogue. , 2008, Journal of the American Chemical Society.

[84]  D. Lloyd,et al.  Synthesis of oligodeoxyribonucleotide N3'-->P5' phosphoramidates. , 1995, Nucleic acids research.

[85]  J. Micklefield,et al.  Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. , 2001, Current medicinal chemistry.

[86]  A. Eschenmoser,et al.  Warum Pentose- und nicht Hexose-Nucleinsäuren??. Teil II. Oligonucleotide aus 2′,3′-Dideoxy-β-D-glucopyranosyl-Bausteinen (‘Homo-DNS’): Herstellung.† , 1992 .

[87]  M. Graham,et al.  An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis Published, JLR Papers in Press, February 16, 2005. DOI 10.1194/jlr.M400492-JLR200 , 2005, Journal of Lipid Research.

[88]  Ruiwen Zhang,et al.  Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? , 2008, Drug discovery today.

[89]  H. Ørum,et al.  Peptide Nucleic Acid , 1997 .

[90]  A. Eschenmoser,et al.  Chemical etiology of nucleic acid structure , 2000 .

[91]  P. Herdewijn,et al.  D-ALTRITOL NUCLEIC ACIDS (ANA) : HYBRIDISATION PROPERTIES, STABILITY, AND INITIAL STRUCTURAL ANALYSIS , 1999 .

[92]  M. Teplova,et al.  Structural basis of cleavage by RNase H of hybrids of arabinonucleic acids and RNA. , 2000, Biochemistry.

[93]  M. Lindholm,et al.  Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates , 2010, Nucleic acids research.

[94]  E. Wickstrom,et al.  Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. , 1990, Journal of biochemical and biophysical methods.

[95]  Dong Yu,et al.  Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties. , 2000, Bioorganic & medicinal chemistry.

[96]  M. Wood,et al.  Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[97]  T. Imanishi,et al.  2'-O,4'-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. , 2002, Bioorganic & medicinal chemistry letters.

[98]  R. Esnouf,et al.  Synthesis and Pairing Properties of Oligonucleotides Containing 3‐Hydroxy‐4‐hydroxymethyl‐1‐cyclohexanyl Nucleosides , 1999 .

[99]  S. Crooke.  Antisense Drug Technology , 2001 .

[100]  M. Gait.  Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues , 2003, Cellular and Molecular Life Sciences CMLS.

[101]  T. C. Bruice,et al.  Solid-phase synthesis of oligopurine deoxynucleic guanidine (DNG) and analysis of binding with DNA oligomers. , 2001, Nucleic acids research.

[102]  B. Shaw,et al.  H-PHOSPHONATE APPROACH FOR SOLID-PHASE SYNTHESIS OF OLIGODEOXYRIBONUCLEOSIDE BORANOPHOSPHATES AND THEIR CHARACTERIZATION , 1998 .

[103]  M. Caruthers,et al.  Synthesis of an oligothymidylate containing boranophosphate linkages , 1998 .

[104]  J. Wengel,et al.  Synthesis of Novel Bicyclo[2.2.1] Ribonucleosides: 2'-Amino- and 2'-Thio-LNA Monomeric Nucleosides. , 1998, The Journal of organic chemistry.

[105]  I. Brukner,et al.  HYBRIDS OF RNA AND ARABINONUCLEIC ACIDS (ANA AND 2'F-ANA) ARE SUBSTRATES OF RIBONUCLEASE H , 1998 .

[106]  N. Kipshidze,et al.  First human experience with local delivery of novel antisense AVI-4126 with Infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from AVAIL study. , 2007, Cardiovascular revascularization medicine : including molecular interventions.

[107]  D. Barawkar,et al.  Synthesis, biophysical properties, and nuclease resistance properties of mixed backbone oligodeoxynucleotides containing cationic internucleoside guanidinium linkages: deoxynucleic guanidine/DNA chimeras. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[108]  G. van Ommen,et al.  Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[109]  Luciano Merlini,et al.  Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[110]  K. Miyashita,et al.  N-Methyl substituted 2',4'- BNANC: a highly nuclease-resistant nucleic acid analogue with high-affinity RNA selective hybridization. , 2007, Chemical communications.

[111]  J. Wengel.  Synthesis of 3‘-C- and 4‘-C-Branched Oligodeoxynucleotides and the Development of Locked Nucleic Acid (LNA) , 1999 .

[112]  J. Kastelein,et al.  Apolipoprotein B synthesis inhibition: results from clinical trials , 2010, Current opinion in lipidology.

[113]  B. Tavitian,et al.  Modulation of the pharmacokinetic properties of PNA: preparation of galactosyl, mannosyl, fucosyl, N-acetylgalactosaminyl, and N-acetylglucosaminyl derivatives of aminoethylglycine peptide nucleic acid monomers and their incorporation into PNA oligomers. , 2003, Bioconjugate chemistry.

[114]  Geoffrey A. Blake,et al.  Molecular Interactions and Hydrogen Bond Tunneling Dynamics: Some New Perspectives , 1993, Science.

[115]  T. C. Bruice,et al.  NANOSECOND MOLECULAR DYNAMICS STUDY OF A POLYCATION RIBONUCLEIC GUANIDINE (RNG) DUPLEXED WITH A COMPLEMENTARY DNA OLIGOMER STRAND , 1997 .

[116]  T. C. Bruice,et al.  Development of potential anticancer agents that target the telomere sequence. , 2010, Bioorganic & medicinal chemistry letters.

[117]  M. Egholm,et al.  Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. , 1991, Science.

[118]  J. Jukema,et al.  Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. , 2010, Journal of the American College of Cardiology.

[119]  M. Caruthers,et al.  Phosphorodithioate DNA as a potential therapeutic drug. , 1993, Science.

[120]  K. Bushby,et al.  Molecular treatments in Duchenne muscular dystrophy. , 2010, Current opinion in pharmacology.

[121]  T. Ishida,et al.  Synthesis of 2′-O,4′-C-Methyleneuridine and -cytidine. Novel Bicyclic Nucleosides Having a Fixed C3′-endo Sugar Puckering. , 2010 .

[122]  S. Mccurdy,et al.  An improved synthesis of oligodeoxynucleotide N3'-->P5' phosphoramidates and their chimera using hindered phosphoramidite monomers and a novel handle for reverse phase purification. , 1998, Nucleic acids research.

[123]  S. Gryaznov,et al.  Oligodeoxyribonucleotide N3'.fwdarw.P5' Phosphoramidates: synthesis and Hybridization Properties , 1994 .

[124]  O. Almarsson,et al.  Design and synthesis of deoxynucleic guanidine: a polycation analogue of DNA. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[125]  T. P. Prakash,et al.  Synthesis and biophysical evaluation of 2',4'-constrained 2'O-methoxyethyl and 2',4'-constrained 2'O-ethyl nucleic acid analogues. , 2010, The Journal of organic chemistry.

[126]  J. Gribben,et al.  5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  S. Freier,et al.  The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. , 1997, Nucleic acids research.

[128]  P. Nielsen,et al.  Analogues of a locked nucleic acid with three-carbon 2',4'-linkages: synthesis by ring-closing metathesis and influence on nucleic acid duplex stability and structure. , 2006, The Journal of organic chemistry.

[129]  Johan T den Dunnen,et al.  Local dystrophin restoration with antisense oligonucleotide PRO051. , 2007, The New England journal of medicine.

[130]  M. Egli,et al.  Interplay of structure, hydration and thermal stability in formacetal modified oligonucleotides: RNA may tolerate nonionic modifications better than DNA. , 2009, Journal of the American Chemical Society.

[131]  B. Monia,et al.  Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals , 2006, Nucleic acids research.

[132]  D. Lloyd,et al.  Oligonucleotide N3'-->P5' phosphoramidates as antisense agents. , 1996, Nucleic acids research.

[133]  M. Egli,et al.  An exocyclic methylene group acts as a bioisostere of the 2'-oxygen atom in LNA. , 2010, Journal of the American Chemical Society.

[134]  A. Silahtaroglu,et al.  Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver , 2007, Nucleic acids research.

[135]  M. Matteucci.  Deoxyoligonucleotide analogs based on formacetal linkages , 1990 .

[136]  D. Barofsky,et al.  Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. , 1996, Antisense & nucleic acid drug development.

[137]  B. Potter,et al.  Stereochemical course of DNA hydrolysis by nuclease S1. , 1983, The Journal of biological chemistry.

[138]  L. Betts,et al.  A Nucleic Acid Triple Helix Formed by a Peptide Nucleic Acid-DNA Complex , 1995, Science.

[139]  Frank Baas,et al.  UvA-DARE ( Digital Academic Repository ) In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid ( LNA ) antisense oligonucleotides , 2017 .

[140]  Raunak,et al.  Chemically modified oligonucleotides with efficient RNase H response. , 2008, Bioorganic & medicinal chemistry letters.

[141]  R. Griffey,et al.  Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. , 1995, The Biochemical journal.

[142]  P. Herdewijn,et al.  1′, 5′ ‐Anhydrohexitol Oligonucleotides: Synthesis, Base Pairing and Recognition by Regular Oligodeoxyribonucleotides and Oligoribonucleotides , 1997 .

[143]  Anton J. Enright,et al.  Efficient inhibition of miR-155 function in vivo by peptide nucleic acids , 2010, Nucleic acids research.

[144]  A. Levin,et al.  Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). , 2006, Oligonucleotides.

[145]  D. Witchell,et al.  Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. , 2009, Journal of medicinal chemistry.

[146]  T. Wada,et al.  A novel method for the synthesis of dinucleoside boranophosphates by a boranophosphotriester method. , 2004, The Journal of organic chemistry.

[147]  G. van Ommen,et al.  Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. , 2007, RNA.

[148]  A. Siwkowski,et al.  Antisense oligonucleotides containing conformationally constrained 2',4'-(N-methoxy)aminomethylene and 2',4'-aminooxymethylene and 2'-O,4'-C-aminomethylene bridged nucleoside analogues show improved potency in animal models. , 2010, Journal of medicinal chemistry.

[149]  T. C. Bruice,et al.  Synthesis of a thymidyl pentamer of deoxyribonucleic guanidine and binding studies with DNA homopolynucleotides. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[150]  S. Obika,et al.  BNAs: novel nucleic acid analogs with a bridged sugar moiety. , 2002, Chemical communications.

[151]  N. Minakawa,et al.  Synthesis and properties of 4′-ThioDNA: unexpected RNA-like behavior of 4′-ThioDNA , 2006, Nucleic acids research.

[152]  T. C. Bruice,et al.  Synthesis of the Polycation Thymidyl DNG, Its Fidelity in Binding Polyanionic DNA/RNA, and the Stability and Nature of the Hybrid Complexes , 1995 .

[153]  S. Stavchansky,et al.  Pharmacokinetics and Biodistribution of a Nucleotide-Based Thrombin Inhibitor in Rats , 1998, Pharmaceutical Research.

[154]  P. Nielsen,et al.  Antisense properties of peptide nucleic acid. , 1999, Biochimica et biophysica acta.

[155]  R. T. Walker,et al.  The synthesis and antiviral activity of some 4'-thio-2'-deoxynucleoside analogues. , 1991, Nucleic Acids Symposium Series.

[156]  Mark J Graham,et al.  Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice , 2008, Circulation.

[157]  P. Herdewijn,et al.  Cyclohexene Nucleic Acids (CeNA): Serum Stable Oligonucleotides that Activate RNase H and Increase Duplex Stability with Complementary RNA , 2000 .

[158]  G. Cote,et al.  Hydrolysis of the O,O-dialkyl phosphorodithioic acids used as extractants in liquid-liquid systems , 1984 .

[159]  P. D. Cook,et al.  Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. , 1995, Nucleic acids research.

[160]  N. Seidah,et al.  A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo , 2010, PloS one.

[161]  W. Pathmasiri,et al.  Conformationally constrained 2'-N,4'-C-ethylene-bridged thymidine (aza-ENA-T): synthesis, structure, physical, and biochemical studies of aza-ENA-T-modified oligonucleotides. , 2006, Journal of the American Chemical Society.

[162]  R. T. Walker,et al.  Synthesis and properties of oligodeoxynucleotides containing the analogue 2'-deoxy-4'-thiothymidine. , 1993, Nucleic acids research.

[163]  R. Strömberg,et al.  Oligoribonucleotide Analogues Containing a Mixed Backbone of Phosphodiester and Formacetal Internucleoside Linkages, Together with Vicinal 2′‐O‐Methyl Groups , 2007, Chembiochem : a European journal of chemical biology.

[164]  B. Lebleu,et al.  Improved cell-penetrating peptide–PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle , 2008, Nucleic acids research.

[165]  M. Caruthers,et al.  Synthesis and Characterization of Dinucleoside Phosphorodithioates. , 1988 .

[166]  P. Herdewijn,et al.  Alpha-homo-DNA and RNA form a parallel oriented non-A, non-B-type double helical structure. , 2001, Chemistry.

[167]  C. Périgaud,et al.  Recent Approaches in the Synthesis of Conformationally Restricted Nucleoside Analogues , 2008 .

[168]  I. Brukner,et al.  Hybrids of RNA and Arabinonucleic Acids (ANA and 2‘F-ANA) Are Substrates of Ribonuclease H J. Am. Chem. Soc. 1998, 120, 12976−12977 , 1998 .

[169]  José Miguel Reyes,et al.  Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  C. Mann,et al.  Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse , 2003, Nature Medicine.

[171]  E. Lesnik,et al.  2'-O-[2-(amino)-2-oxoethyl] oligonucleotides. , 2003, Organic letters.

[172]  O. Dahl,et al.  Solid phase synthesis of oligodeoxyribonucleoside phosphorodithioates from thiophosphoramidites. , 1991, Nucleic acids research.

[173]  M. Bergström,et al.  Biodistribution of 68Ga-labeled LNA-DNA mixmer antisense oligonucleotides for rat chromogranin-A. , 2008, Oligonucleotides.

[174]  T. Imanishi,et al.  Synthesis and properties of 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) as effective antisense oligonucleotides. , 2003, Bioorganic & medicinal chemistry.

[175]  S. Obika,et al.  Synthesis and properties of 3'-amino-2',4'-BNA, a bridged nucleic acid with a N3'-->P5' phosphoramidate linkage. , 2008, Bioorganic & medicinal chemistry.

[176]  T. Wada,et al.  Solid-phase synthesis of stereoregular oligodeoxyribonucleoside phosphorothioates using bicyclic oxazaphospholidine derivatives as monomer units. , 2008, Journal of the American Chemical Society.

[177]  D. G. Davis,et al.  NMR solution structure of a peptide nucleic acid complexed with RNA. , 1994, Science.

[178]  S. Beaucage,et al.  3H-1,2-Benzodithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphorothioates , 1990 .

[179]  A. Rabinowitz,et al.  Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology , 2006, Nature Medicine.

[180]  M. Stephenson,et al.  Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[181]  J. Summerton,et al.  Morpholino antisense oligomers: design, preparation, and properties. , 1997, Antisense & nucleic acid drug development.

[182]  Y. Hari,et al.  Stable oligonucleotide-directed triplex formation at target sites with CG interruptions: strong sequence-specific recognition by 2',4'-bridged nucleic-acid-containing 2-pyridones under physiological conditions. , 2002, Chemistry.

[183]  T. C. Bruice,et al.  Binding studies of cationic thymidyl deoxyribonucleic guanidine to RNA homopolynucleotides. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[184]  M. Matteucci,et al.  Synthesis and hybridization study of a boranophosphate-linked oligothymidine deoxynucleotide , 1997 .

[185]  Piet Herdewijn,et al.  1',5'-anhydrohexitol oligonucleotides: Hybridisation and strand displacement with oligoribonucleotides, interaction with RNase H and HIV reverse transcriptase , 1997 .

[186]  S. Takeda,et al.  Progress in muscular dystrophy research with special emphasis on gene therapy , 2010, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[187]  P. Iversen,et al.  Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[188]  T. C. Bruice,et al.  Binding studies of cationic uridyl ribonucleic guanidine (RNG) to DNA. , 2005, Bioorganic & medicinal chemistry letters.

[189]  T. James,et al.  Structural effect of complete [Rp]-phosphorothioate and phosphorodithioate substitutions in the DNA strand of a model antisense inhibitor-target RNA complex. , 1999, Journal of molecular biology.

[190]  D. Gorenstein,et al.  Synthesis, NMR and structure of oligonucleotide phosphorodithioates , 1991 .

[191]  A. Levin,et al.  Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. , 2004, Journal of pharmaceutical sciences.

[192]  B. Monia,et al.  Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice Published, JLR Papers in Press, January 22, 2007. , 2007, Journal of Lipid Research.

[193]  M. Manoharan,et al.  2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo. , 2004, Nucleic acids research.

[194]  M. Manoharan,et al.  Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides. , 2008, Journal of medicinal chemistry.

[195]  T. Wada,et al.  Diastereocontrolled synthesis of dinucleoside phosphorothioates using a novel class of activators, dialkyl(cyanomethyl)ammonium tetrafluoroborates. , 2002, Journal of the American Chemical Society.

[196]  P. Nielsen.  Peptide Nucleic Acid. A Molecule with Two Identities , 2010 .

[197]  J. Eisen,et al.  Controlling morpholino experiments: don't stop making antisense , 2008, Development.

[198]  W. Stec,et al.  AUTOMATED SOLID-PHASE SYNTHESIS, SEPARATION, AND STEREOCHEMISTRY OF PHOSPHOROTHIOATE ANALOGS OF OLIGODEOXYRIBONUCLEOTIDES , 1985 .

[199]  M. Manoharan,et al.  Synthesis of 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl] modified nucleosides and oligonucleotides. , 2002, The Journal of organic chemistry.

[200]  G. Hardee,et al.  Oral delivery of antisense oligonucleotides in man. , 2008, Journal of pharmaceutical sciences.

[201]  Y. Takeshima,et al.  Intravenous Infusion of an Antisense Oligonucleotide Results in Exon Skipping in Muscle Dystrophin mRNA of Duchenne Muscular Dystrophy , 2006, Pediatric Research.

[202]  J. Wengel,et al.  Universality of LNA-mediated high-affinity nucleic acid recognition , 1998 .

[203]  M. Reitz,et al.  Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[204]  Satoshi Obika,et al.  A 2',4'-Bridged Nucleic Acid Containing 2-Pyridone as a Nucleobase: Efficient Recognition of a C⋅G Interruption by Triplex Formation with a Pyrimidine Motif. , 2001, Angewandte Chemie.

[205]  M. Gait,et al.  miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. , 2007, RNA.

[206]  T. C. Bruice,et al.  Design and synthesis of ribonucleic guanidine: a polycationic analog of RNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[207]  Anthony D. Keefe,et al.  Building oligonucleotide therapeutics using non-natural chemistries. , 2006, Current opinion in chemical biology.

[208]  R. T. Walker,et al.  DUPLEX- AND TRIPLEX-FORMING PROPERTIES OF 4′-THIO-MODIFIED OLIGODEOXYNUCLEOTIDES , 1997 .

[209]  J. Rice,et al.  Conformation of formacetal and 3'-thioformacetal nucleotide linkers and stability of their antisense RNA.DNA hybrid duplexes. , 1997, Biochemistry.

[210]  A. Rabinowitz,et al.  Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[211]  F. Zoulim,et al.  Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro. , 2008, Antiviral research.

[212]  B. Shaw,et al.  Boron-containing nucleic acids. 2. Synthesis of oligodeoxynucleoside boranophosphates , 1990 .

[213]  M. Nerenberg,et al.  Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. , 1994, The Journal of biological chemistry.

[214]  C. Len,et al.  Synthesis of bicyclonucleosides having a C-C bridge. , 2008, Chemical reviews.

[215]  F. Akdim,et al.  Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. , 2010, The American journal of cardiology.